Patents by Inventor Si Tuen Lee-Hoeflich

Si Tuen Lee-Hoeflich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGF-BETA INHIBITORS AND USE THEREOF
    Publication number: 20230050148
    Abstract: The present disclosure provides TGF? inhibitor therapy for treating immunosuppressive conditions, such as cancer. Selection of suitable therapy and patients who are likely to benefit from such therapy are also disclosed, as well as methods of treating cancer and methods of predicting and monitoring therapeutic response. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 16, 2023
    Inventors: Ashish Kalra, Thomas Schurpf, Adam Fogel, Christopher Brueckner, Alan Buckler, Constance Martin, Si Tuen Lee-Hoeflich
  • ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS
    Publication number: 20220305134
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 29, 2022
    Inventors: Anthony Edward BOITANO, Matthew BURGER, Susan E. CELLITTI, Michael P. COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Yunho JIN, Si Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO, Ben WEN
  • Antibody drug conjugates for ablating hematopoietic stem cells
    Patent number: 11357864
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Ben Wen, Anthony E. Boitano, Matthew Burger, Susan E. Cellitti, Michael P. Cooke, Catrin Finner, Bernhard Hubert Geierstanger, Yunho Jin, Si Tuen Lee-Hoeflich, HongNgoc Thi Pham, Siew Ho Schleyer, Kathrin Tissot, Tetsuo Uno
  • ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS
    Publication number: 20210228731
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Application
    Filed: June 19, 2019
    Publication date: July 29, 2021
    Inventors: Anthony Edward BOITANO, Matthew T. BURGER, Susan E. CELLITTI, Michael Paul COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Si-Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO, Yongqin WAN, Ben WEN, Qiang ZHANG
  • GENE EXPRESSION MARKERS OF TUMOR RESISTANCE TO HER2 INHIBITOR TREATMENT
    Publication number: 20190323089
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicant: Genentech, Inc.
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS
    Publication number: 20190321483
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 24, 2019
    Inventors: Ben WEN, Anthony E. BOITANO, Matthew BURGER, Susan E. CELLITTI, Michael P. COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Yunho JIN, Si Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO
  • Gene expression markers of tumor resistance to HER2 inhibitor treatment
    Patent number: 10385405
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: August 20, 2019
    Assignee: Genentech, Inc.
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • GENE EXPRESSION MARKERS OF TUMOR RESISTANCE TO HER2 INHIBITOR TREATMENT
    Publication number: 20170073777
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 16, 2017
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • Gene expression markers of tumor resistance to HER2 inhibitor treatment
    Patent number: 9551033
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: January 24, 2017
    Assignee: Genentech, Inc.
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • Gene expression markers of tumor resistance to HER2 inhibitor treatment
    Publication number: 20110151454
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Application
    Filed: August 12, 2010
    Publication date: June 23, 2011
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern
  • GENE EXPRESSION MARKERS OF TUMOR RESISTANCE TO HER2 INHIBITOR TREATMENT
    Publication number: 20100298156
    Abstract: The present invention concerns markers of resistance of HER2 expressing tumors to treatment with HER2 inhibitors, such as HER2 antibodies, including trastuzumab.
    Type: Application
    Filed: June 4, 2008
    Publication date: November 25, 2010
    Inventors: Si Tuen Lee-Hoeflich, Howard Stern